A team at Purdue University has shown that a liquid monomer injected directly into the motor cortex of a mouse will polymerise inside the living tissue into a soft, electrically conductive mesh, using the iron in the animal’s own blood as the catalyst. The resulting structure can then be used to modulate neuronal firing on demand with near-infrared light shone through the skull.

The work, led by chemist Jianguo Mei and published this week in Science under the title “Blood-catalyzed n-doped polymers for reversible optical neural control,” describes a chemistry that removes a long-standing constraint in bioelectronics: conductive polymers have traditionally been fabricated on a bench and then implanted as a pre-formed device. Mei’s group instead starts with a small molecule — a monomer of n-doped poly(benzodifurandione), or n-PBDF — delivered as a liquid. Heme-containing proteins such as haemoglobin and myoglobin provide the iron that catalyses oxidative coupling of the monomers into a polymer network, which settles around neurons at the injection site.

In mice injected in the motor cortex, the material formed stable electrode deposits without signs of inflammation, loss of neurons or changes in behaviour. Imaging and blood-vessel assays supported the safety profile. Electrophysiological recordings showed that n-PBDF shifted the activity of sodium and potassium channels — the ion currents that govern how readily a neuron fires.

The functional readout used a learned task. Mice had been trained to press a lever for a reward. When the researchers delivered pulses of near-infrared light from outside the skull, the polymer converted the light into local electrical signals that temporarily suppressed cortical activity, and the animals failed to execute the task. Turning the light off restored normal function and the mice resumed pressing the lever as before. The effect was reversible across multiple cycles.

Two features of the approach matter for brain-computer interfaces. The first is that the device itself is formed inside the target tissue, through a syringe rather than a craniotomy and electrode array. The second is that the material is inherently photoresponsive: the same polymer that conforms to neurons can be driven from outside the body with light, without introducing a virus or genetically modifying the neurons themselves, as optogenetics requires.

That places the work in the broader shift visible across the field over the past year, from rigid silicon probes toward materials designed to meet tissue on its own mechanical and biochemical terms. Neuronoff’s needle-delivered wireless electrodes, injectable mesh electronics from other groups, and hydrogel-based bioelectrostimulators for deep brain stimulation are moving along parallel tracks. Mei’s contribution is to use the body’s own chemistry — specifically, the catalytic iron in blood — as the assembly step.

Significant questions remain before the approach can be tested in humans. The Science paper reports temporary, reversible suppression of activity rather than high-bandwidth recording of neural signals, which is what clinical BCIs require. Long-term stability beyond the initial studies, the uniformity of polymerisation across larger brain volumes, and compatibility with existing neurosurgical workflow have yet to be established. There is also a regulatory category question: an in-situ assembled bioelectronic does not fit cleanly into either the drug or device frameworks that govern implantable neurotechnology today.

If the chemistry holds up in longer and larger studies, however, the implication is meaningful. The biggest single cost in implantable BCIs — and the biggest deterrent for most patients who are candidates for them — is the surgery. A syringe-delivered electrode that assembles itself from a monomer and a little blood would remove a substantial part of that barrier.